{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:33:14Z","timestamp":1762079594305,"version":"3.37.3"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T00:00:00Z","timestamp":1496102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Intern Med"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The use of non\u2010vitamin K antagonist oral anticoagulants (<jats:styled-content style=\"fixed-case\">NOAC<\/jats:styled-content>s) for stroke prophylaxis in atrial fibrillation (<jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content>) is increasing rapidly. We compared characteristics of <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> patients initiated on <jats:styled-content style=\"fixed-case\">NOAC<\/jats:styled-content>s versus vitamin K antagonists (<jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content>s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using Danish nationwide registry data, we identified <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> patients initiating either a <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> or a <jats:styled-content style=\"fixed-case\">NOAC<\/jats:styled-content> from 22 August 2011 until 30 September 2016. We compared patient characteristics including age, gender, comorbidities, concomitant pharmacotherapy and <jats:styled-content style=\"fixed-case\">CHA<\/jats:styled-content><jats:sub>2<\/jats:sub><jats:styled-content style=\"fixed-case\">DS<\/jats:styled-content><jats:sub>2<\/jats:sub>\u2010<jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>c and <jats:styled-content style=\"fixed-case\">HAS<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">BLED<\/jats:styled-content> scores in patients initiated on a <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content>, dabigatran, rivaroxaban or apixaban. Differences were examined using multivariable logistic regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study population comprised 51\u00a0981 <jats:styled-content style=\"fixed-case\">AF<\/jats:styled-content> patients of whom 19\u00a0989 (38.5%) were initiated on a <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content>, 13\u00a0242 (25.5%) on dabigatran, 8475 (16.3%) on rivaroxaban and 10\u00a0275 (19.8%) on apixaban. Those patients initiated on apixaban had higher mean\u00a0\u00b1\u00a0<jats:styled-content style=\"fixed-case\">SD CHA<\/jats:styled-content><jats:sub>2<\/jats:sub><jats:styled-content style=\"fixed-case\">DS<\/jats:styled-content><jats:sub>2<\/jats:sub>\u2010<jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>c scores than those initiated on a <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> (3.1\u00a0\u00b1\u00a01.6 vs. 2.9\u00a0\u00b1\u00a01.6). Those initiated on dabigatran had lower mean <jats:styled-content style=\"fixed-case\">CHA<\/jats:styled-content><jats:sub>2<\/jats:sub><jats:styled-content style=\"fixed-case\">DS<\/jats:styled-content><jats:sub>2<\/jats:sub>\u2010<jats:styled-content style=\"fixed-case\">VAS<\/jats:styled-content>c scores (2.7\u00a0\u00b1\u00a01.6) than all other groups. Patients with a history of a prior stroke were significantly more likely to be initiated on a <jats:styled-content style=\"fixed-case\">NOAC<\/jats:styled-content> compared with a <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> [odds ratio (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>) 1.35, 95% confidence interval (<jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>) 1.28\u20131.43]. By contrast, patients with a history of myocardial infarction were less likely to be initiated on a <jats:styled-content style=\"fixed-case\">NOAC<\/jats:styled-content> compared with a <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content> 0.72, 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.67\u20130.77).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Atrial fibrillation patients who were initiated on apixaban had higher stroke risk scores than patients initiated on <jats:styled-content style=\"fixed-case\">VKA<\/jats:styled-content>s. Interestingly, opposite results were found for dabigatran.<\/jats:p><\/jats:sec>","DOI":"10.1111\/joim.12628","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T07:55:36Z","timestamp":1494230136000},"page":"164-174","source":"Crossref","is-referenced-by-count":21,"title":["Initiation of anticoagulation in atrial fibrillation: which factors are associated with choice of anticoagulant?"],"prefix":"10.1111","volume":"282","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4960-5804","authenticated-orcid":false,"given":"A.","family":"Gundlund","sequence":"first","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Staerk","sequence":"additional","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. L.","family":"Fosb\u00f8l","sequence":"additional","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"},{"name":"Department of Cardiology University Hospital of Copenhagen Rigshospitalet Copenhagen Denmark"},{"name":"The Danish Heart Foundation Rigshospitalet Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Gadsb\u00f8ll","sequence":"additional","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sindet\u2010Pedersen","sequence":"additional","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. N.","family":"Bonde","sequence":"additional","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. H.","family":"Gislason","sequence":"additional","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"},{"name":"The Danish Heart Foundation Rigshospitalet Copenhagen Denmark"},{"name":"The National Institute of Public Health University of Southern Denmark Odense Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Olesen","sequence":"additional","affiliation":[{"name":"Department of Cardiology Herlev and Gentofte Hospital Hellerup Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-7-199910050-00003"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-9-199411010-00009"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.1.41"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-11-0768"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000040"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu225"},{"key":"e_1_2_8_13_1","first-page":"899","article-title":"Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark","volume":"38","author":"Gadsb\u00f8ll K","year":"2017","journal-title":"Eur Heart J"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.12.027"},{"key":"e_1_2_8_15_1","first-page":"342","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"31","author":"Olesen JB","year":"2011","journal-title":"BMJ"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep31477"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000535"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-310"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.05.013"},{"key":"e_1_2_8_20_1","unstructured":"NBV 2016 \u2010 Dansk Cardiologisk Selskab \u2013 14.Peroral antikoagulansbehandling [Internet]. [cited 2016 Sep 13]. Available from:http:\/\/nbv.cardio.dk\/ak."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.3.281"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.055970"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000515"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2016.1164689"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-002758"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.581"}],"container-title":["Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjoim.12628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/joim.12628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:27:44Z","timestamp":1696264064000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/joim.12628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/joim.12628"],"URL":"https:\/\/doi.org\/10.1111\/joim.12628","archive":["Portico"],"relation":{},"ISSN":["0954-6820","1365-2796"],"issn-type":[{"type":"print","value":"0954-6820"},{"type":"electronic","value":"1365-2796"}],"subject":[],"published":{"date-parts":[[2017,5,30]]}}}